A review of 25 years experience with the NovoPen® family of insulin pens in the management of diabetes mellitus

Clinical Drug Investigation

Volumn 30, Issue 10, 2010, Pages 643-674

  Hyllested Winge, Jacob ^a   Jensen, Klaus H ^a   Rex, Jørn ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Antihyperglycaemics; Diabetes mellitus; Insulin; Insulin pen.; therapeutic use; treatment

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; NEUTRAL INSULIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN;

ABSENCE OF SIDE EFFECTS; CLINICAL TRIAL; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION PAIN; INJECTION SITE DISCOMFORT; INSULIN TREATMENT; METABOLIC REGULATION; PATIENT COMPLIANCE; PEDIATRICS; POSTPRANDIAL STATE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYRINGE; ADOLESCENT; ADULT; AGE; AGED; BLOOD; CHILD; EQUIPMENT DESIGN; FEMALE; MALE; METABOLISM; MIDDLE AGED; PATIENT SATISFACTION; PRESCHOOL CHILD; PRODUCT SAFETY; SOCIAL BEHAVIOR; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHILD; CHILD, PRESCHOOL; CONSUMER PRODUCT SAFETY; DIABETES MELLITUS; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITY OF LIFE; SOCIAL BEHAVIOR; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955586555     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11584360-000000000-00000     Document Type: Review

References (81)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 Sep 30; 329 (14): 977-986
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 Sep 12; 352 (9131): 837-853
3. Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care 2004 Oct; 27 (10): 2495-2497
4. Rex J, Jensen KH, Lawton SA. A review of 20 years' experience with the NovoPen family of insulin injection devices. Clin Drug Investig 2006; 26 (7): 367-401
5. Arendt-Nielsen L, Egekvist H, Bjerring P. Pain following controlled cutaneous insertion of needles with different diameters. Somatosens Mot Res 2006 Mar-Jun; 23 (1-2): 37-43
6. Iwanaga M, Kamoi K. Patient perceptions of injection pain and anxiety: a comparison of NovoFine 32-gauge tip 6 mm and Micro Fine Plus 31-gauge 5 mm needles. Diabetes Technol Ther 2009 Feb; 11 (2): 81-86
7. Berger AS, Saurbrey N, Kuhl C, et al. Clinical experience with a new device that will simplify insulin injections. Diabetes Care 1985 Jan-Feb; 8 (1): 73-76
8. Engstrom LHK. Insulin pen for administration of isophane insulin. Practical Diabetes 1990; 7: 162-164
9. Saurbrey N, Arnold-Larsen S, Moller-Jensen B, et al. Comparison of continuous subcutaneous insulin infusion with multiple insulin injections using the NovoPen. Diabet Med 1988 Mar; 5 (2): 150-153
10. Saurbrey N, Berger A, Kuhl C. The NovoPen: a practical tool for simplifying multiple injection insulin therapy. Acta Paediatr Scand Suppl 1985; 320: 64-65
11. Gnanalingham M, Newland P, Smith C. An evaluation of NovoPen, BD-Pen, and syringe devices at small doses of insulin [abstract no. 118]. British Diabetic Association's Medical and Scientific Section Spring Meeting; 1998 Mar 25-27; Edinburgh
12. Gnanalingham MG, Newland P, Smith CP. Accuracy and reproducibility of low dose insulin administration using pen-injectors and syringes. Arch Dis Child 1998 Jul; 79 (1): 59-62
13. Keith K, Nicholson D, Rogers D. Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump. Clin Pediatr (Phila) 2004 Jan-Feb; 43 (1): 69-74
14. Arslanoglu I, Saka N, Bundak R, et al. A comparison of the use of premixed insulins in pen-injectors with conventional patient-mixed insulin treatment in children and adolescents with IDDM: is there a decreased risk of night hypoglycemia? J Pediatr Endocrinol Metab 2000 Mar; 13 (3): 313-318
15. Bohannon NJ. Insulin delivery using pen devices: simple-to- use tools may help young and old alike. Postgrad Med 1999 Oct 15; 106 (5): 57-8, 61-4, 68
16. Gall MA, Mathiesen ER, Skott P, et al. Effect of multiple insulin injections with a pen injector on metabolic control and general well-being in insulin-dependent diabetes mel- litus. Diabetes Res 1989 Jun; 11 (2): 97-101
17. Murray D, Keenan P, Gayer E, et al. An evaluation of a multiple-injection regimen using the novopen in diabetes mellitus [abstract]. Irish J Med Sci 1988; 157: 372
18. Murray DP, Keenan P, Gayer E, et al. A randomized trial of the efficacy and acceptability of a pen injector. Diabet Med 1988 Nov; 5 (8): 750-754
19. Small M, MacRury S, Boal A, et al. Comparison of conventional twice daily subcutaneous insulin administration and a multiple injection regimen (using the NovoPen) in insulin-dependent diabetes mellitus. Diabetes Res 1988 Jun; 8 (2): 85-89
20. Tallroth G, Karlson B, Nilsson A, et al. The influence of different insulin regimens on quality of life and metabolic control in insulin-dependent diabetics. Diabetes Res Clin Pract 1989 Jan 3; 6 (1): 37-43
21. Tubiana-Rufi N, Levy-Marchal C, Mugnier E, et al. Long term feasibility of multiple daily injections with insulin pens in children and adolescents with diabetes. Eur J Pe- diatr 1989 Nov; 149 (2): 80-83
22. Dahl-Jorgensen K, Hanssen KF, Mosand R, et al. The "insulin pen": comparison with multiple injection treatment with syringe. Practical Diabetes 1986; (3): 90-91
23. Henderson M, Tindall H. Evaluation of consumer satisfaction and quality of life in patients changing to Novopen II. Practical Diabetes 1990; 7: 206-208
24. Masson EA, McAughey D, Davies D, et al. The use of multiple insulin injection therapy using 'NovoPen' in a routine out-patient setting. Diabetes Res Clin Pract 1989 Jun 20; 7 (1): 57-60
25. Stewart K, Wilson M, Rider J. Insulin delivey devices. J Pharm Prac 2004; 17: 20-28
26. Walters DP, Smith PA, Marteau TM, et al. Experience with NovoPen, an injection device using cartridged insulin, for diabetic patients. Diabet Med 1985 Nov; 2 (6): 496-497
27. Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther 1998 May-Jun; 20 (3): 486-496
28. Kadiri A, Chraibi A, Marouan F, et al. Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents. Diabetes Res Clin Pract 1998 Jul; 41 (1): 15-23
29. Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006 Oct; 28 (10): 1712-25; discussion 1710-1711
30. Pawaskar MD, Camacho FT, Anderson RT, et al. Health care costs and medication adherence associated with initiation ofinsulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther 2007; 29 Spec No: 1294-1305
31. Hanas R. Type 1 diabetes in children, adolescents and young adults. 2nd ed. London: Class Publishing; 2004
32. Houtzagers CM, Berntzen PA, van der Stap H, et al. Efficacy and acceptance of two intensified conventional insulin therapy regimens: a long-term cross-over comparison. Diabet Med 1989 Jul; 6 (5): 416-421
33. Houtzagers CM, Visser AP, Berntzen PA, et al. Multiple daily insulin injections improve self-confidence. Diabet Med 1989 Aug; 6 (6): 512-519
34. ® 1.5 in Indian women with gestational diabetes mellitus. In: 16th International Diabetes Federation Congress; 1997 Jul 20-25; Helsinki
35. Su CC, Chen HS, Lin HD. Glycemic control with different premixed insulin in Taiwanese people with type two diabetes mellitus. J Chin Med Assoc 2003 Mar; 66 (3): 155-159
36. Spijker A, Hoekstra J, Erkelens D. The insulin pen: a new device for multiple insulin injections. Transplant Proc 1986; 18: 1689-1690
37. Valk NK, Cerny G, Sieber J, et al. Efficacy and safety performance of the Innovo insulin doser. Diabetes Technol Ther 2004 Feb; 6 (1): 53-58
38. Katoulis E, Makris G, Ioannou J, et al. Longterm (2 years) comparison of Basal-Bolus Novopen and conventional regime in insulin dependent diabetics [abstract]. Diabetes 1991 (40); 456
39. ® [abstract]. Diabetes 2006; 55: A456
40. Asakura T, Seino H, Jensen KH. Patient acceptance and issues of education of two durable insulin pen devices. Diabetes Technol Ther 2008 Aug; 10 (4): 299-304
41. ® Pro in patients and healthcare professionals [abstract]. Diabetes Technol Ther 2005; 7 (2): 390
42. ® 4, a new insulin pen system, among insulin naive users [abstract]. Diabetes 2006; 55 SUPPL. 1: A456
43. Asakura T, Seino H. Assessment of dose selection attributes with audible notification in insulin pen devices. Diabetes Technol Ther 2005 Aug; 7 (4): 620-626
44. ® 3 users [abstract]. 67th Scientific Sessions of the American Diabetes Association; 2007 June 22-26; Chicago (IL), A532
45. Kolendorf K, Beck-Nielsen H, Oxenboll B. Clinical experience with NovoPen II and insulin Protaphane HM Penfill. Postgrad Med J 1988; 64 SUPPL. 3: 14-6; discussion 21
46. Bak JF, Nielsen OH, Pedersen O, et al. Multiple insulin injections using a pen injector versus insulin pump treatment in young diabetic patients. Diabetes Res 1987 Nov; 6 (3): 155-158
47. Goke B, Gamba G, Erdtsieck RJ, et al. NovoPen 4 offers superior performance, handling and acceptance compared with NovoPen 3 in insulin-treated diabetes patients [abstract]. Diabetes Technol Ther 2005; 7 (2): 379
48. Olsen B, Lilleore S. NovoPen Echo for the delivery of insulin in paediatric patients: a comparison of usability, functionality and preference among patients, their parents and healthcare professionals [abstract]. International Society for Paediatric and Adolescent Diabetes (ISPAD) Annual Meeting; 2009 Aug 30-Sep 1; Ljubljana
49. Jensen T, Moller L, Ortved Andersen O. Metabolic control and patient acceptability of multiple insulin injections using NovoPen cartridge-packed insulin. Practical Diabetes 1986; 3: 302-306
50. Lunt H, Smith RB. Multiple dose insulin regimen using the NovoPen [letter]. N Z Med J 1986 May 28; 99 (802): 379
51. Chang G, Chia J, Rahayu S, et al. Evaluating the use of the Novopen 3 insulin delivery system in Singaporean diabetes subjects. In: 17th International Diabetes Federation Congress; 2000 Nov 5-10; Mexico City
52. Fovenyi J, Szoverffy G, Thaisz E, et al. Experiences with functional insulin substitution: a follow-up study on control and patient compliance. Acta Med Hung 1992; 49 (1-2): 53-64
53. Hyer S, Froyd H, Kohner E. Effect of the NovoPen on glycemic control and patient independence in diabetics with visual impairment. Practical Diabetes 1988; 5: 197-199
54. ® in a homeless population: efficacy, preference and biosafety. In: 60th Scientific Sessions of the American Diabetes Association; 2000 Jun 9-13; San Antonio (TX)
55. Wilk T, Mora P, Chaney S, et al. Use of an insulin pen by homeless patients with diabetes mellitus. J Am Acad Nurse Pract 2002; 14: 372-379
56. Hardy K, Jones K, Gill G, et al. NovoPen worsens blood glucose control in female diabetics [abstract]. Diabetic Med 1990; 7 SUPPL. 1: 23
57. Sommerfeldt E, Oygard R, Sander J, et al. Novopen: a useful aid also for blind diabetic patients. Diabetes Care 1989 Apr; 12 (4): 306-307
58. ® 4 increases diabetes treatment satisfaction during insulin therapy: results of an observational study in the Netherlands [abstract]. 67th Scientific Sessions of the American Diabetes Association; 2007 Jun 22-26; Chicago (IL), A532
59. Distiller LA, Robertson LI, Moore R, et al. A bolus/basal multiple injection regimen in type I diabetes: a multicentre trial using a new 'fountain-pen' device for short-acting human insulin as well as long-acting human insulin. S Afr Med J 1987 Jun 20; 71 (12): 749-752
60. Houtzagers CM, van der Velde EA. Multiple daily insulin injections: a multicentre study on acceptability and efficacy. Neth J Med 1988 Aug; 33 (1-2): 16-25
61. Dinneen SF, Cronin CC, O'Sullivan DJ. Long term efficacy of a pen injector. Ir J Med Sci 1991 Sep; 160 (9): 286-287
62. Dunn PJ, Jury DR. Multiple dose insulin regimen using the NovoPen: initial experience and approximate dose requirements. N Z Med J 1986 Apr 9; 99 (799): 226-230
63. Jefferson IG, Marteau TM, Smith MA, et al. A multiple injection regimen using an insulin injection pen and pre- filled cartridged soluble human insulin in adolescents with diabetes. Diabet Med 1985 Nov; 2 (6): 493-495
64. Jenkins HR, Hinton JL, Williams H, et al. A study of metabolic control and patient acceptability in adolescent diabetics using the NovoPen. Practical Diabetes 1989; 6: 14-15
65. Salardi S, Cacciari E, Zucchini S, et al. Modifications of metabolic control in type 1 diabetic children and adolescents: experience over the last 20 years. J Pediatr En- docrinol Metab 1997 Nov-Dec; 10 (6): 569-578
66. Romanian Young Diabetics Study Team (RYDST). Mix- tard 30 HM Penfill insulin treatment in selected young insulin-dependent diabetes mellitus patients. Rom J Intern Med 1997; 35: 99-113
67. Gordon D, Wilson M, Paterson KR, et al. An assessment of the accuracy of NovoPen 1 delivery after prolonged use. Diabet Med 1990 May; 7 (4): 364-366
68. Lteif AN, Schwenk WF. Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care 1999 Jan; 22 (1): 137-140
69. Santiago OM, Khutoryansky NM, Bilbo CM, et al. Accuracy and precision of the NovoPen 3 insulin delivery device after mechanical and temperature stresses. Endocr Pract 2002 Sep-Oct; 8 (5): 351-355
70. Kristensen CM, Donsmark M. Dose accuracy and durability of the NovoPen 4 insulin delivery device before and after simulation of 5 years of use and under various stress conditions. Clin Ther 2009 Dec; 31 (12): 2819-2823
71. Asakura T, Seino H. Injection pressure of various combinations of insulin self-injectors and needles [abstract]. Diabetes 2005; 54 SUPPL. 1: A129
72. Donsmark M, Herold L, Kristensen CM. A comparison of injection force and dosage scale size between NovoPen 3 and NovoPen 4. Diabetes Technol Ther 2009 Sep; 11 (9): 581-585
73. Toraishi K, Yuizono Y, Nakamura N, et al. Force requirements and insulin delivery profiles offour injection devices. Diabetes Technol Ther 2005 Aug; 7 (4): 629-635
74. Costello C, Calabrese G, Fedele D, et al. Use of premixed insulin among the elderly: reduction of errors in patient preparation of mixtures. Diabetes Care 1992; 15 (11): 1628-1630
75. Newman KD, Weaver MT. Insulin measurement and preparation among diabetic patients at a county hospital. Nurse Pract 1994 Mar; 19 (3): 44-5, 48
76. Diglas J, Feinbock C, Winkler F, et al. Reduced pain perception with Pen Mate, an automatic needle insertion device for use with an insulin pen. Pract Diabetes Int 1999; 16: 39-41
77. Hornquist JO, Wikby A, Andersson PO, et al. Insulin-pen treatment, quality of life and metabolic control: retrospective intra-group evaluations. Diabetes Res Clin Pract 1990 Nov-Dec; 10 (3): 221-230
78. Macleod JM, White KE, Tate H, et al. Measurement of glomerular volume in needle biopsy specimens: the ESPRIT Study Group (European Study of the Progression of Renal Disease in Type 1 Diabetes). Nephrol Dial Transplant 2000 Feb; 15 (2): 239-243
79. Schwartz S, Hassman D, Shelmet J, et al. A multicenter, open-label, randomized, two-period crossover trial com-paring glycemic control, satisfaction, and preference achieved with a 31 gauge x 6 mm needle versus a 29 gauge x 12.7 mm needle in obese patients with diabetes mellitus. Clin Ther 2004 Oct; 26 (10): 1663-78 80.
80. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy: the basis of patient reluctance. Diabetes Care 1997 Mar; 20 (3): 292-298
81. Liebermeister H, Sammler A. Problems of the elderly, insulin injecting diabetic patients in ambulatory care. Versi- cherungsmedizin 1990 Apr 1; 42 (2): 59-64